PMID- 21453265
OWN - NLM
STAT- MEDLINE
DCOM- 20110829
LR  - 20191112
IS  - 1875-5704 (Electronic)
IS  - 1567-2018 (Linking)
VI  - 8
IP  - 3
DP  - 2011 May
TI  - Part I: targeted particles for cancer immunotherapy.
PG  - 261-73
AB  - Dendritic cells (DCs) are the key antigen presenting cells that link innate and 
      adaptive immunity. In the periphery, DCs capture antigens, process them and 
      migrate into the regional lymph nodes where they could initiate antigen specific 
      T cell immune responses. Immunotherapeutic strategies that aim to deliver tumor 
      antigens specifically to DCs could not only boost anti-tumor immune responses but 
      also could alleviate non-specific immune activation and/or unwanted side effects. 
      Nano-sized particulate delivery systems are efficient modalities that can deliver 
      tumor antigens to DCs in a targeted and specific manner. This review will provide 
      general information on the rationale behind targeting antigens to DCs and the 
      crucial role of DCs in initiating antigen specific T cell responses. Different 
      strategies that have been employed in delivering antigens to DCs will be also 
      discussed. A special emphasis will be put on specific targeting of cancer vaccine 
      formulations to DC-specific receptors (e.g. CD11c, CD40, Fcgamma, CCR6, pathogenic 
      recognition receptors such as Toll-like receptors (TLRs) and C-type lectin 
      receptors (CLRs)).
FAU - Hamdy, Samar
AU  - Hamdy S
AD  - Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, Alberta 
      T6G 2N8, Canada.
FAU - Haddadi, Azita
AU  - Haddadi A
FAU - Ghotbi, Zahra
AU  - Ghotbi Z
FAU - Hung, Ryan W
AU  - Hung RW
FAU - Lavasanifar, Afsaneh
AU  - Lavasanifar A
LA  - eng
GR  - MOP 42407/Canadian Institutes of Health Research/Canada
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - United Arab Emirates
TA  - Curr Drug Deliv
JT  - Current drug delivery
JID - 101208455
RN  - 0 (Antigens, Neoplasm)
RN  - 0 (Cancer Vaccines)
SB  - IM
MH  - Animals
MH  - Antigens, Neoplasm/immunology
MH  - Cancer Vaccines/administration & dosage/immunology
MH  - Dendritic Cells/immunology
MH  - Humans
MH  - Immunotherapy/*methods
MH  - Nanoparticles/*administration & dosage
MH  - Neoplasms/*immunology/*therapy
EDAT- 2011/04/02 06:00
MHDA- 2011/08/30 06:00
CRDT- 2011/04/02 06:00
PHST- 2010/07/20 00:00 [received]
PHST- 2010/11/27 00:00 [accepted]
PHST- 2011/04/02 06:00 [entrez]
PHST- 2011/04/02 06:00 [pubmed]
PHST- 2011/08/30 06:00 [medline]
AID - BSP/CDD/E-Pub/00086 [pii]
AID - 10.2174/156720111795256101 [doi]
PST - ppublish
SO  - Curr Drug Deliv. 2011 May;8(3):261-73. doi: 10.2174/156720111795256101.